HomeAbout

TL;DR CNBC


Bristol Myers Squibb beats on revenue, launches $1.5 billion cost cuts as it posts quarterly loss - TL;DR CNBC

Bristol Myers Squibb beats on revenue, launches $1.5 billion cost cuts as it posts quarterly loss

Publishing timestamp: 2024-04-25 12:26:45


Summary

Bristol Myers Squibb reported first-quarter revenue that topped expectations, but swung to a quarterly loss due to one-time charges. The company plans to cut $1.5 billion in costs by 2025 and reinvest in drug development. They will lay off employees, discontinue some drug programs, and focus on key drug brands. Despite revenue growth driven by sales of Eliquis and newer drugs, the company faces pressure to launch new drugs to offset potential revenue loss from top-selling treatments.


Sentiment: MIXED

Tickers: BMYPFE

Keywords: earningsbiotech and pharmaceuticalspfizer incbusiness newsbreaking newsbiotechnologybristol-myers squibb copharmaceuticalshealth care industrybusiness

Source: https://www.cnbc.com/2024/04/25/bristol-myers-squibb-bmy-earnings-q1-2024.html


Developed by Leo Phan